

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Edmund
Tracy-Gene G. Durkin
Michael A. Cimbalia
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millorig
Donald J. Featherstone
Lawrence B. Bugalsky
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro
Donald R. Banowit
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly M. Reddick
Theodore A. Wood

Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuiller
Rae Lynn Phegeman
Jane Shershenovich
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
LuAnne M. DeSantis
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston
Arik W. Ledford
Jessica L. Parezo

Timothy A. Doyle*
Gaby L. Longworth*
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katrina Y. Pel Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Eric D. Hayes
Michelle K. Holoubek
Robert H. DeSelms
Simon A. Elliott
Julia A. Heider
Mita Mukherjee
Scott M. Woodhouse

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

* Admitted only in Maryland
* Admitted only in Virginia
* Practice Limited to Federal Agencies

March 15, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8762
INTERNET ADDRESS:
NLEITH@SKGF.COM

Art Unit To Be Assigned

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


Re: U.S. Utility Patent Application
Application No. 10/734,625; Filed: December 15, 2003
For: **Lipoxygenase Inhibitors as Hypolipidemic and Anti-Hypertensive Agents**
Inventors: **ALLAN et al.**
Our Ref: **1633.0400002/SRL/NJL**

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. PTO-1449 citing 67 documents; and
3. Copies of 40 cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.



MAR 15 2004

FORM PTO-1449

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Z ₂ F	AA1	4,231,938	11/04/1980	Monaghan <i>et al.</i>			06/15/1979
	AB1	4,294,926	10/13/1981	Monaghan <i>et al.</i>			01/23/1980
	AC1	4,319,039	03/09/1982	Albers-Schonberg			08/11/1980
	AD1	4,346,227	08/24/1982	Terahara <i>et al.</i>			06/05/1981
	AE1	4,393,075	07/12/1983	Terao <i>et al.</i>			03/26/1981
	AF1	4,410,629	10/18/1983	Terahara <i>et al.</i>			02/24/1982
	AG1	4,444,784	04/24/1984	Hoffman <i>et al.</i>			12/18/1980
	AH1	4,537,859	08/27/1985	Terahara <i>et al.</i>			11/18/1982
	AI1	4,681,893	07/21/1987	Roth			05/30/1986
	AJ1	4,738,986	04/19/1988	Kneen <i>et al.</i>			03/10/1987
Z ₂ F	AK1	4,820,850	04/11/1989	Verhoeven <i>et al.</i>			07/10/1987

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
Z ₂ F	AL1	WO 84/02131					Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Z ₂ F	AR	1	Ashida, Y., <i>et al.</i> , "Pharmacological Profile of AA-861, A 5-Lipoxygenase Inhibitor," <i>Prostaglandins</i> 26:955-972, Elsevier Science (1983)
Z ₂ F	AS	1	Azhar, S., <i>et al.</i> , "Alteration of the Adrenal Antioxidant Defense System During Aging in Rats," <i>J. Clin. Invest.</i> 96:1414-1424, American Society for Clinical Investigation (1995)
Z ₂ F	AT	1	Babu, P.S., and Srinivasan, K., "Hypolipidemic action of curcumin, the active principle of turmeric (<i>Curcuma longa</i>) in streptozotocin induced diabetic rats," <i>Mol. Cell. Biochem.</i> 166:169-175, Kluwer Academic Publishers (1997)


EXAMINER

zachary Fay

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
	FIRST NAMED INVENTOR Allan <i>et al.</i>	
	FILING DATE December 15, 2003	ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Z.F.	AA2	4,911,165	03/27/1990	Lennard <i>et al.</i>			12/12/1988
	AB2	4,916,239	04/10/1990	Treiber			07/19/1988
	AC2	4,929,437	05/29/1990	Tobert			02/02/1989
	AD2	5,030,447	07/09/1991	Joshi <i>et al.</i>			03/31/1988
	AE2	5,081,138	01/14/1992	Gillard <i>et al.</i>			12/09/1987
	AF2	5,118,853	06/02/1992	Lee <i>et al.</i>			02/26/1991
	AG2	5,177,080	01/05/1993	Angerbauer <i>et al.</i>			11/26/1991
	AH2	5,180,589	01/19/1993	Joshi <i>et al.</i>			05/20/1991
	AI2	5,189,164	02/23/1993	Kapa <i>et al.</i>			02/20/1990
	AJ2	5,273,995	12/28/1993	Roth			02/26/1991
Z.F.	AK2	5,290,946	03/01/1994	Lee <i>et al.</i>			11/23/1992

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Z.F.	AR	2	Bantle, J.P., <i>et al.</i> , "Effects of dietary fructose on plasma lipids in healthy subjects," <i>Am. J. Clin. Nutr.</i> 72:1128-1134, American Society for Clinical Investigation (2000)
Z.F.	AS	2	Bhattacharjee, P., <i>et al.</i> , "The Effects of a Novel Series of Selective Inhibitors of Arachidonate 5-Lipoxygenase on Anaphylactic and Inflammatory Responses," <i>Ann. New York Acad. Sci.</i> , 307-320, The New York Academy of Sciences (1988)
Z.F.	AT	2	Brindley, D.N., <i>et al.</i> , "The Involvement of Glucocorticoids in Regulating the Activity of Phosphatidate Phosphohydrolase and the Synthesis of Triacylglycerols in the Liver," <i>Biochem. J.</i> 180: 195-199, The Biochemical Society (1979)

EXAMINER <i>Zahner Faj</i>	DATE CONSIDERED 7/23/07
-------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 3 of 13



FORM PTO-1449

ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
FIRST NAMED INVENTOR Allan <i>et al.</i>	
FILING DATE December 15, 2003	ART UNIT To Be Assigned


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
ZrF	AA3	5,342,952	08/30/1994	Butler <i>et al.</i>			10/12/1993
	AB3	5,354,772	10/11/1994	Kathwala			11/24/1993
	AC3	5,356,896	10/18/1994	Kabadi <i>et al.</i>			12/22/1992
	AD3	5,489,691	02/06/1996	Butler <i>et al.</i>			05/15/1995
ZrF	AE	6,191,169 B1	02/20/2001	Nadler <i>et al.</i>			11/03/1997
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
ZrF	AR	3	Das, U.N., "Is Metabolic Syndrome X an Inflammatory Condition," <i>Exp. Biol. Med.</i> 227:989-997, Society for Experimental Biology and Medicine (December 2002)
	AS	3	Feingold, K.R., <i>et al.</i> , "Beneficial effects of cytokine induced hyperlipidemia," <i>Z. Ernährungswiss</i> 37:66-74, Steinkopff Verlag (1998)
ZrF	AT	3	Gillard, J., <i>et al.</i> , "L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3- <i>t</i> -butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor," <i>Can. J. Physiol. Pharmacol.</i> 67: 456-464, National Research Council of Canada (1989)

EXAMINER <i>Zachary F...</i>	DATE CONSIDERED 7/23/07
------------------------------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


	Page 4 of 13	
	ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
	FIRST NAMED INVENTOR Allan <i>et al.</i>	
	FILING DATE December 15, 2003	ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
Z.F	AR	4	Gowri, M.S., <i>et al.</i> , "Masoprocil Lowers Blood Pressure in Rats With Fructose-Induced Hypertension," <i>Am. J. Hypertension</i> , 12:744-746, Elsevier Science (1999)
Z.F	AS	4	Gowri, M.S., <i>et al.</i> , "Masoprocil decreases rat lipolytic activity by decreasing the phosphorylation of HSL," <i>Am. J. Physiol. Endocrinol. Metab.</i> 279:E593-E600, American Physiological Society (2000)
Z.F	AT	4	Guha, M., <i>et al.</i> , "Molecular Mechanisms of Tumor Necrosis Factor α Gene Expression in Monocytic Cells via Hyperglycemia-Induced Oxidant Stress-dependent and -independent Pathways," <i>J. Biol. Chem.</i> 275:17728-17739, The American Society for Biochemistry and Molecular Biology, Inc. (2000)

EXAMINER 	DATE CONSIDERED 7/23/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL
FIRST NAMED INVENTOR
Allan *et al.*APPLICATION NO.
10/734,625FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

2rf	AR	5	Hallfrisch, J., "Metabolic effects of dietary fructose," <i>FASEB J.</i> 4:2652-2660, Federation of American Societies for Experimental Biology (1990)
2rf	AS	5	Hammes, H.-P., <i>et al.</i> , "Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy," <i>Nat. Med.</i> 9:294-299, Nature Publishing Company (March 2003)
2rf	AT	5	Han, T.S., <i>et al.</i> , "Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study," <i>Diabetes Care</i> 25:2016-2021, American Diabetes Association (November 2002)


EXAMINER

Zaburk Fay

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 <p>FORM PTO-1449</p> <p>INFORMATION DISCLOSURE STATEMENT</p>	ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
	FIRST NAMED INVENTOR Allan <i>et al.</i>	
	FILING DATE December 15, 2003	ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Z.F	AR	6	Hirosumi, J., <i>et al.</i> , "A central role for JNK in obesity and insulin resistance," <i>Nature</i> 420:333-336, Nature Publishing Company (November 2002)
Z.F	AS	6	Inoue, I., <i>et al.</i> , "Effect of Troglitazone (CS-045) and Bezafibrate on Glucose Tolerance, Liver Glycogen Synthase Activity, and β -Oxidation in Fructose-Fed Rats," <i>Metabolism</i> 44:1626-1630, W.B. Saunders Company (1995)
Z.F	AT	6	Jonkers, I.J., <i>et al.</i> , "Severe Hypertriglyceridemia with Insulin Resistance Is Associated with Systemic Inflammation: Reversal with Bezafibrate Therapy in a Randomized Controlled Trial," <i>Am. J. Med.</i> 112: 275-280, Excerpta Medica, Inc. (March 2002)


EXAMINER 	DATE CONSIDERED 7/23/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Page 7 of 13							
<div style="text-align: center;">  </div> <div style="text-align: center;"> FORM PTO-1449 INFORMATION ON DISCLOSURE STATEMENT </div>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">ATTY. DOCKET NO. 1633.0400002/SRL/NJL</td> <td style="width: 50%;">APPLICATION NO. 10/734,625</td> </tr> <tr> <td colspan="2">FIRST NAMED INVENTOR Allan <i>et al.</i></td> </tr> <tr> <td>FILING DATE December 15, 2003</td> <td>ART UNIT To Be Assigned</td> </tr> </table>	ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625	FIRST NAMED INVENTOR Allan <i>et al.</i>		FILING DATE December 15, 2003	ART UNIT To Be Assigned
ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625						
FIRST NAMED INVENTOR Allan <i>et al.</i>							
FILING DATE December 15, 2003	ART UNIT To Be Assigned						

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)					
Z ₂ F	AR	I	Knox, A.M., <i>et al.</i> , "Control of Hepatic Triacylglycerol Synthesis. Diurnal Variations in Hepatic Phosphatidate Phosphohydrolase Activity and in the Concentrations of Circulating Insulin and Corticosterone in Rats," <i>Biochem. J.</i> 180: 441-443, The Biochemical Society (1979)		
Z ₂ f	AS	I	Kraemer, F.B., <i>et al.</i> , "Adrenal Neutral Cholesteryl Ester Hydrolase: Identification, Subcellular Distribution, and Sex Differences," <i>Endocrinol.</i> 143:801-806, The Endocrine Society (March 2002)		
Z ₂ F	AT	I	Mangaloglu, L., <i>et al.</i> , "Treatment With Atorvastatin Ameliorates Hepatic Very-Low-Density Lipoprotein Overproduction in an Animal Model of Insulin Resistance, the Fructose-Fed Syrian Golden Hamster: Evidence That reduced Hypertriglyceridemia Is Accompanied by Improved Hepatic Insulin Sensitivity," <i>Metabolism</i> 51: 409-418, W.B. Saunders (April 2002)		
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">EXAMINER Zaburk Fay</td> <td style="width: 40%;">DATE CONSIDERED 7/23/07</td> </tr> </table>				EXAMINER Zaburk Fay	DATE CONSIDERED 7/23/07
EXAMINER Zaburk Fay	DATE CONSIDERED 7/23/07				
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>					



MAR 15 2004

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Zuf	AR	8	McIntosh, M., <i>et al.</i> , "Opposing Actions of Dehydroepiandrosterone and Corticosterone in Rats," <i>Proc. Soc. Exp. Med.</i> 221:198-206, Society for Experimental Biology and Medicine (1999)
	AS	8	Medicherla, R., <i>et al.</i> , "Impaired activation of AP-1 and altered expression of constituent proteins in rat adrenal during ageing," <i>Mech. Aging Dev.</i> 122:1169-1186, Elsevier Science Ireland Ltd. (June 2001)
Zuf	AT	8	Memon, R.A., <i>et al.</i> , "Tumor Necrosis Factor Mediates the Effects of Endotoxin on Cholesterol and Triglyceride Metabolism in Mice," <i>Endocrinol.</i> 132:2246-2253, The Endocrine Society (1993)


EXAMINER

Zuf Fg

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



MAR 15 2004

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJLAPPLICATION NO.
10/734,625FIRST NAMED INVENTOR
Allan *et al.*FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Z ₂ F	AR	9	Nagai, Y., <i>et al.</i> , "Amelioration of high fructose-induced metabolic derangements by activation of PPAR α ," <i>Am. J. Physiol. Endocrinol. Metab.</i> 282:E1180-E1190, American Physiological Society (January 2002)
Z ₂ F	AS	9	Okamoto, T., <i>et al.</i> , "Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin," <i>FASEB J.</i> 16:1928-1930, Federation of American Societies for Experimental Biology (December 2002)
Z ₂ F	AT	9	Park, O.-J., <i>et al.</i> , "Mechanisms of fructose-induced hypertriglyceridaemia in the rat," <i>Biochem. J.</i> 282:753-757, The Biochemical Society (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL

APPLICATION NO.
10/734,625

FIRST NAMED INVENTOR
Allan *et al.*

FILING DATE
December 15, 2003

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

22F	AR	10	Radmark, O., <i>et al.</i> , "The Inhibitory Effects of BW 755C on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes," <i>FEBS Lett.</i> 110: 213-215, Elsevier/North Holland (1980)
22F	AS	10	Rouzer, C.A., <i>et al.</i> , "MK886, a Potent and Specific Leukotriene Biosynthesis Inhibitor Blocks and Reverses the Membrane Association of 5-Lipoxygenase in Ionophore-challenged Leukocytes," <i>J. Biol. Chem.</i> 265:1436-1442, The American Society for Biochemistry and Molecular Biology, Inc. (1990)
22F	AT	10	Scribner, K.A., <i>et al.</i> , "Masoprocol Decreases Serum Triglyceride Concentrations in Rats With Fructose-Induced Hypertriglyceridemia," <i>Metabolism</i> 49:1106-1110, W.B. Saunders Company (2000)

EXAMINER


22F

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 11 of 13




FORM PTO-1449


INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1633.0400002/SRL/NJL	APPLICATION NO. 10/734,625
FIRST NAMED INVENTOR Allan <i>et al.</i>	
FILING DATE December 15, 2003	ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
24f	AR	11	Tagari, P., <i>et al.</i> , "Assessment of the <i>in vivo</i> biochemical efficacy of orally active leukotriene biosynthesis inhibitors," <i>Agents Action</i> 40:62-71, Birkhäuser Verlag (1993)
22f	AS	11	Tercyak, A.M., "Determination of cholesterol and cholesterol esters," <i>J. Nutr. Biochem.</i> 2:281-292, Butterworth-Heinemann (1991)
25f	AT	11	Uchida, K., <i>et al.</i> , "Activation of Stress Signaling Pathways by the End Product of Lipid Peroxidation," <i>J. Biol. Chem.</i> 274: 2234-2242, The American Society for Biochemistry and Molecular Biology, Inc. (1999)
<div style="display: flex; justify-content: space-between;"> <div>EXAMINER </div> <div>DATE CONSIDERED 7/23/07</div> </div>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL
FIRST NAMED INVENTOR
Allan *et al.*APPLICATION NO.
10/734,625FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


ZF	AR	12	Uysal, K.T., <i>et al.</i> , "Protection from obesity-induced insulin resistance in mice lacking TNF- α function," <i>Nature</i> 389:610-614, Nature Publishing Company (1997)
ZF	AS	12	Ventre, J., <i>et al.</i> , "Targeted Disruption of the Tumor Necrosis Factor- α Gene," <i>Diabetes</i> 46:1526-1531, American Diabetes Association (1997)
ZF	AT	12	Woo, C.-H., <i>et al.</i> , "Tumor Necrosis Factor- α Generates Reactive Oxygen Species via a Cytosolic Phospholipase A ₂ -linked Cascade," <i>J. Biol. Chem.</i> 275: 32357-32362, The American Society for Biochemistry and Molecular Biology, Inc. (2000)

EXAMINER

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1633.0400002/SRL/NJL
FIRST NAMED INVENTOR
Allan *et al.*APPLICATION NO.
10/734,625FILING DATE
December 15, 2003ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ZF	AR	13	Yoshimoto, T., <i>et al.</i> , "2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a Selective Inhibitor of the 5-Lipoxygenase Reaction and the Biosynthesis of Slow-Reacting Substance of Anaphylaxis," <i>Biochim. Biophys. Acta</i> 713:470-473, Elsevier Biomedical Press (1982)
ZF	AS	13	Yuan, M., <i>et al.</i> , "Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of <i>Ikkβ</i> ," <i>Science</i> 293:1673-1677, American Association for the Advancement of Science (August 2001)
ZF	AT	13	Zavaroni, I., <i>et al.</i> , "Studies of the Mechanism of Fructose-Induced Hypertriglyceridemia in the Rat," <i>Metabolism</i> 31:1077-1083, Grune & Stratton (1982)

EXAMINER

DATE CONSIDERED

7/23/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.